Immunogen Inc 's Revenue in the fiscal year 2022 $ 108.78 millions
Immunogen Inc 's Revenue in the fiscal year 2021 $ 69.86 millions
Immunogen Inc 's Revenue in the fiscal year 2020 $ 132.30 millions
Immunogen Inc 's Revenue in the fiscal year 2019 $ 82.27 millions
Immunogen Inc 's Revenue in the fiscal year 2018 $ 53.45 millions
IMGN Revenue third quarter 2023 Y/Y Growth Comment
Immunogen inc achieved in the third quarter 2023, above Company average Revenue surge of 637.48% year on year, to $ 113.43 millions.
Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue growth. While Immunogen Inc ' s Revenue doubling of 637.48% ranks overall at the positon no. 63 in the third quarter 2023.
Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023
Immunogen Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
365.19 %
37.46 %
-100 %
(Dec 31 2017)
IMGN's III. Quarter Q/Q Revenue Comment
Immunogen inc achieved in the III. Quarter 2023 below company average Revenue jump of 36.41% quarter on quarter, to $ 113.43 millions.
Although the III. Quarter 2023 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 8.62% growth in the III. Quarter a year ago
Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Immunogen Inc 's Revenue growth quarter on quarter, overall rank is 303.
Immunogen inc achieved in the III. Quarter 2023 below company average Revenue jump of 36.41% quarter on quarter, to $ 113.43 millions.
III. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 8.62% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Immunogen Inc 's Revenue growth quarter on quarter, overall rank is 303.
Immunogen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2023)
12 Months Ending (Jun 30 2023)
12 Months Ending (Mar 31 2023)
12 Months Ending (Dec 31 2022)
12 Months Ending (Sep 30 2022)
Cumulative Revenue 12 Months Ending
$ 287.61
$ 189.56
$ 120.57
$ 108.78
$ 95.61
Y / Y Revenue Growth (TTM)
200.83 %
111.94 %
30.73 %
55.72 %
-25.11 %
Year on Year Revenue Growth Overall
Ranking
# 357
# 189
# 36
# 2733
# 382
Seqeuential Revenue Change (TTM)
51.72 %
57.22 %
10.84 %
13.78 %
6.89 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1635
# 1190
# 68
# 1137
# 2683
Cumulative Revenue growth Comment
With 200.83% annual Revenue growth, Immunogen Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.
In the Healthcare sector 114 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 189 to 357.
With 200.83% annual Revenue growth, Immunogen Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.
In the Healthcare sector 114 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 189 to 357.
About Immunogen Inc Revenue Growth Rates (IMGN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1,110.36%